{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:42:39Z","timestamp":1787928159412,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius Foundation, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Training Group Translational Research Innovation - Pharma (TRIP)"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["CH 806\/1-1; HI 1837\/1-1"],"award-info":[{"award-number":["CH 806\/1-1; HI 1837\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Goethe University Hospital Frankfurt"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jaut.2016.02.007","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T10:45:21Z","timestamp":1456483521000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model"],"prefix":"10.1016","volume":"69","author":[{"given":"Peter","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef M.","family":"Pfeilschifter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Hintermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-7976","authenticated-orcid":false,"given":"Urs","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2016.02.007_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000282080","article-title":"Epidemiology of non-alcoholic fatty liver disease","volume":"28","author":"Bellentani","year":"2010","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jaut.2016.02.007_bib2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2016.02.007_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000282084","article-title":"Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases","volume":"28","author":"Powell","year":"2010","journal-title":"Dig. Dis."},{"key":"10.1016\/j.jaut.2016.02.007_bib4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2016.02.007_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","article-title":"Pathological features of fatty liver disease","volume":"147","author":"Yeh","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.02.007_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12016-013-8383-x","article-title":"Autoimmune features in metabolic liver disease: a single-center experience and review of the literature","volume":"45","author":"Tsuneyama","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2016.02.007_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1740-2557-4-3","article-title":"The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis\/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders","volume":"4","author":"Papamichalis","year":"2007","journal-title":"J.\u00a0Autoimmun. Dis."},{"key":"10.1016\/j.jaut.2016.02.007_bib8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/14656566.2014.931938","article-title":"Current and prospective pharmacotherapy for autoimmune hepatitis","volume":"15","author":"Czaja","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jaut.2016.02.007_bib9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2012.11.002","article-title":"Autoimmune hepatitis: A comprehensive review","volume":"41","author":"Liberal","year":"2013","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.02.007_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11894-011-0236-2","article-title":"Diagnosis and treatment of autoimmune hepatitis","volume":"14","author":"Vierling","year":"2012","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.jaut.2016.02.007_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bpg.2011.10.004","article-title":"Diagnostic criteria for autoimmune hepatitis","volume":"25","author":"Lohse","year":"2011","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.02.007_bib12","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2016.02.007_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2217\/imt.13.5","article-title":"The role of autoantibodies in autoimmune hepatitis type 2","volume":"5","author":"Christen","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaut.2016.02.007_bib14","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI113949","article-title":"Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1","volume":"83","author":"Manns","year":"1989","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jaut.2016.02.007_bib15","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1073\/pnas.85.21.8256","article-title":"Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II","volume":"85","author":"Zanger","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2016.02.007_bib16","first-page":"1","article-title":"The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice","volume":"60","author":"Hintermann","year":"2012","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.jaut.2016.02.007_bib17","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20071859","article-title":"Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection","volume":"205","author":"Holdener","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jaut.2016.02.007_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.gastro.2010.04.053","article-title":"Advances in the Diagnosis, Pathogenesis and Management of Autoimmune Hepatitis","volume":"139","author":"Czaja","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2016.02.007_bib19","series-title":"Absence of CXCL10 or CCL5 Has Opposite Effects on the Severity of Autoimmune Hepatitis in the CYP2D6 Mouse Model","author":"Ehser","year":"2016"},{"key":"10.1016\/j.jaut.2016.02.007_bib20","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.4049\/jimmunol.166.12.7023","article-title":"A\u00a0dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis","volume":"166","author":"Christen","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jaut.2016.02.007_bib21","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.3390\/ijms140611963","article-title":"Vitro and in\u00a0Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"14","author":"Kanuri","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2016.02.007_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/0023677215570078","article-title":"Mouse models of metabolic liver injury","volume":"49","author":"Ramadori","year":"2015","journal-title":"Lab. Anim."},{"key":"10.1016\/j.jaut.2016.02.007_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2012.11.001","article-title":"Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis","author":"Ehser","year":"2013","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.02.007_bib24","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/j.1572-0241.2004.30444.x","article-title":"The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease","volume":"99","author":"Adams","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.02.007_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jaut.2016.02.007_bib26","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s00535-005-1711-z","article-title":"Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?","volume":"40","author":"Yatsuji","year":"2005","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.jaut.2016.02.007_bib27","doi-asserted-by":"crossref","first-page":"893026","DOI":"10.1155\/2012\/893026","article-title":"Role of adaptive immunity in alcoholic liver disease","volume":"2012","author":"Albano","year":"2012","journal-title":"Int. J. Hepatol."},{"key":"10.1016\/j.jaut.2016.02.007_bib28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/ijo.2012.141","article-title":"Increased adipose tissue hypoxia and capacity for angiogenesis and inflammation in young diet-sensitive C57 mice compared with diet-resistant FVB mice","volume":"37","author":"Kim","year":"2013","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.jaut.2016.02.007_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0035-1550065","article-title":"Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications","volume":"35","author":"Angulo","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jaut.2016.02.007_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/CCO.0000000000000042","article-title":"Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer","volume":"26","author":"Lade","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jaut.2016.02.007_bib31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.02.007_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2013.05.001","article-title":"Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6","volume":"44","author":"Hintermann","year":"2013","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.jaut.2016.02.007_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1042\/CS20100008","article-title":"Significance of serum adiponectin levels in patients with chronic liver disease","volume":"119","author":"Balmer","year":"2010","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.jaut.2016.02.007_bib34","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1074\/jbc.M114.598011","article-title":"Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion","volume":"290","author":"Ramezani-Moghadam","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jaut.2016.02.007_bib35","doi-asserted-by":"crossref","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Stojsavljevic","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jaut.2016.02.007_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116300099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841116300099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:13:59Z","timestamp":1760256839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841116300099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"alternative-id":["S0896841116300099"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2016.02.007","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2016.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}